Literature DB >> 19525887

Platinum pathway.

Sharon Marsh1, Howard McLeod, Eileen Dolan, Sunita J Shukla, Cara A Rabik, Li Gong, Tina Hernandez-Boussard, Xing Jian Lou, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19525887      PMCID： PMC4153753          DOI： 10.1097/FPC.0b013e32832e0ed7

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  29 in total

1.  Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1.

Authors:  Tahar van der Straaten; Dinemarie Kweekel; Marco Tiller; Judith Bogaartz; Henk-Jan Guchelaar
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

2.  Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma.

Authors:  Charles Lu; Margaret R Spitz; Hua Zhao; Qiong Dong; Mylene Truong; Joe Y Chang; George R Blumenschein; Waun K Hong; Xifeng Wu
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

3.  Survival and SOS induction in cisplatin-treated Escherichia coli deficient in Pol II, RecBCD and RecFOR functions.

Authors:  Resham Bhattacharya; Doris J Beck
Journal:  DNA Repair (Amst)       Date:  2002-11-03

4.  Glutathione S-transferase polymorphisms and survival in primary malignant glioma.

Authors:  M Fatih Okcu; Mano Selvan; Li-E Wang; Linda Stout; Rodrigo Erana; Gladstone Airewele; Phyllis Adatto; Kenneth Hess; Francis Ali-Osman; Morris Groves; Alfred W K Yung; Victor A Levin; Qingyi Wei; Melissa Bondy
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

5.  Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.

Authors:  Rui Medeiros; Deolinda Pereira; Noémia Afonso; Carlos Palmeira; Cristina Faleiro; Carlos Afonso-Lopes; Margarida Freitas-Silva; André Vasconcelos; Sandra Costa; Teresa Osório; Carlos Lopes
Journal:  Int J Clin Oncol       Date:  2003-06       Impact factor: 3.402

6.  Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.

Authors:  Goli Samimi; Nissi M Varki; Sharon Wilczynski; Roohangiz Safaei; David S Alberts; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

7.  XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

Authors:  Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Wei Zhou; Li Su; John C Wain; Thomas J Lynch; Donna S Neuberg; David C Christiani
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

8.  Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.

Authors:  Kiyotaka Yoh; Genichiro Ishii; Tomoyuki Yokose; Yuji Minegishi; Kohji Tsuta; Koichi Goto; Yutaka Nishiwaki; Tetsuro Kodama; Moritaka Suga; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

9.  Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.

Authors:  S Arnould; I Hennebelle; P Canal; R Bugat; S Guichard
Journal:  Eur J Cancer       Date:  2003-01       Impact factor: 9.162

10.  Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy.

Authors:  S Sakano; T Wada; H Matsumoto; S Sugiyama; R Inoue; S Eguchi; H Ito; C Ohmi; H Matsuyama; K Naito
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640
View more
  26 in total

1.  Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.

Authors:  Wei-Ping Ji; Neng-Bin He
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.

Authors:  Katja Goričar; Viljem Kovač; Janez Jazbec; Branko Zakotnik; Janez Lamovec; Vita Dolžan
Journal:  OMICS       Date:  2015-03

Review 3.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

4.  Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.

Authors:  Joel L Weissfeld; Brenda Diergaarde; Tomoko Nukui; Shama Buch; Arjun Pennathur; Mark A Socinski; Jill M Siegfried; Marjorie Romkes
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

5.  Using Drosophila melanogaster to identify chemotherapy toxicity genes.

Authors:  Elizabeth G King; Galina Kislukhin; Kelli N Walters; Anthony D Long
Journal:  Genetics       Date:  2014-09       Impact factor: 4.562

6.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

Review 7.  FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.

Authors:  Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Pavel Soucek
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 8.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

9.  Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.

Authors:  Jing Zhou; Zhi-yue Liu; Cun-bao Li; Shang Gao; Li-hong Ding; Xin-lin Wu; Zhao-yang Wang
Journal:  Tumour Biol       Date:  2014-12-28

10.  A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.

Authors:  Christine H Chung; Michelle A Rudek; Hyunseok Kang; Shanthi Marur; Pritish John; Nancy Tsottles; Sarah Bonerigo; Andy Veasey; Ana Kiess; Harry Quon; Anthony Cmelak; Barbara A Murphy; Jill Gilbert
Journal:  Oral Oncol       Date:  2015-12-17       Impact factor: 5.337
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.